United Therapeutics
Open
$574.29
Prev. Close
$574.29
High
$574.89
Low
$574.29
Market Snapshot
$24.59B
18.4
26.42
$2.88B
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,400 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
emptyResult
United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. The company is headquartered in Silver Spring, Maryland and currently employs 1,400 full-time employees. The firm markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.
Recently from Cashu
Tyvaso Study Shows Significant Lung Function Improvement, Boosting United Therapeutics Stock
Tyvaso's Breakthrough in Respiratory Health: A Game Changer for Patients United Therapeutics makes headlines with its recent study demonstrating the efficacy of nebulized Tyvaso (treprostinil) in impr…
Tyvaso's Efficacy Highlights United Therapeutics' Impact on Respiratory Health
Tyvaso's Promising Impact on Lung Function Enhances United Therapeutics' Role in Respiratory Health Recent findings from a clinical study underscore the critical role of United Therapeutics’ nebulized…
Employee Welfare: A Rising Focus in Healthcare Strategy and Corporate Responsibility
Commitment to Employee Welfare: A Key Trend in the Healthcare Sector Recent industry reports underscore a significant trend in the corporate realm, particularly relevant for companies like United Ther…
United Therapeutics Innovates Lung Health Solutions Amidst Biotech Industry Advances
BioPharma Breakthrough: United Therapeutics Expands Role in Lung Health United Therapeutics Corporation is on the forefront of innovation in the biotechnology sector, particularly in the development o…